

Accepted Manuscript

Title: Allogeneic Transplantation for Acute Myeloid Leukemia in CR1

Author: Elihu Estey

PII: S1083-8791(17)31677-4

DOI: <https://doi.org/10.1016/j.bbmt.2017.12.773>

Reference: YBBMT 54958


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 2-12-2017

Accepted date: 5-12-2017

Please cite this article as: Elihu Estey, Allogeneic Transplantation for Acute Myeloid Leukemia in CR1, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/10.1016/j.bbmt.2017.12.773>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Commentary

Allogeneic Transplantation for Acute Myeloid Leukemia in CR1

Elihu Estey, M.D.

Division of Hematology University of Washington School of Medicine and Clinical Research

Division Fred Hutchinson Cancer Research Center, Seattle, WA U.S.A

eestey@uw.edu

Keywords: Acute Myeloid Leukemia, population-based, allogenic stem-cell transplantation, comparative effectiveness, survival, chemotherapy

The advisability of allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first CR (CR1) is an increasingly important subject given the greater ability to safely perform reduced-intensity/non myeloablative HCT in older subjects¹ and its extension to unrelated donors. The latter has complicated conventional donor-no donor analyses designed to account for the “guarantee time” HCT recipients, but not chemotherapy-only subjects, must live prior to HCT². In this issue of BBMT Østgård et al.³ use the more appropriate Mantel-Byar method, crediting to chemotherapy follow-up time prior to HCT². They also performed landmark analyses, with subjects receiving HCT after a 200- or, alternatively, 365-day landmark considered in the chemotherapy only group. Each of these methods, combined with multivariate analyses, found, confirming other recent studies^{4,5}, HCT in CR1 associated with less relapse, longer survival and longer relapse-free survival, regardless of age (15- 60 vs 60-70) and cytogenetics (“intermediate” vs. “adverse”, with HCT not performed in CR1 in cases with “favorable” cytogenetics). Choice of donor (matched related vs. matched unrelated) and intensity of conditioning did not affect conclusions.

This important paper benefits from use of the Danish National Acute Leukemia Registry

Download English Version:

<https://daneshyari.com/en/article/8430227>

Download Persian Version:

<https://daneshyari.com/article/8430227>

[Daneshyari.com](https://daneshyari.com)